Pharmacy- Page 21

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020

Pharmacy

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results

by The FINANCIAL

November 16, 2020

2 mins read

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

The FINANCIAL — Metagenomi, a next generation gene editing company launched by

by The FINANCIAL

November 12, 2020

1 min read

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

The FINANCIAL — On the occasion of the World Health Assembly, the world’s

by The FINANCIAL

November 12, 2020

1 min read

Pharmacy

GSK announces Board and Committee changes

The FINANCIAL -- GSK on July 21 announces that Dr Laurie Glimcher has been appointed to the Board of the Company as a Non-Executive Director and has been deemed a Scientific and Medical Expert.

by The FINANCIAL

July 21, 2017

1 min read

Pharmacy

Abbott Laboratories Reveals 36% Gain In Q2 Earnings

The FINANCIAL -- Abbott on July 20 announced financial results for the second quarter ended June 30, 2017.

by The FINANCIAL

July 20, 2017

5 mins read

Pharmacy

NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma

The FINANCIAL -- Teva Pharmaceutical Industries Ltd. on July 20 announced that the National Institute for Health and Care Excellence (NICE) in England has recommended CINQAERO (reslizumab) in its Final Appraisal Determination (FAD). CINQAERO is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody

by The FINANCIAL

July 20, 2017

1 min read

Pharmacy

Johnson & Johnson Reports 2017 Second-Quarter Results

The FINANCIAL -- Johnson & Johnson on July 18 announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016.

by The FINANCIAL

July 18, 2017

4 mins read

Pharmacy

Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders

The FINANCIAL -- Teva Pharmaceutical Industries Ltd. announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier on July 13.

by The FINANCIAL

July 14, 2017

2 mins read

Pharmacy

Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ

The FINANCIAL -- Pfizer Inc. announced on July 13 that the supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis (UC), has been accepted for filing by the

by The FINANCIAL

July 14, 2017

1 min read

Pharmacy

FDA Advisory Committee Votes in Favor of Pfizer’s MYLOTARG for Acute Myeloid Leukemia

The FINANCIAL -- Pfizer Inc. on July 11 announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk:benefit profile for MYLOTARG (gemtuzumab ozogamicin) 3 mg/m2 on days 1,

by The FINANCIAL

July 12, 2017

1 min read

Pharmacy

Bayer and Netafim develop new smart irrigation approach

The FINANCIAL -- Bayer and the Israeli company Netafim are joining forces to enhance the application of crop protection products while supplying crops with water in the most efficient way.

by The FINANCIAL

July 12, 2017

2 mins read

Pharmacy

FDA Grants Full Approval for BLINCYTO

The FINANCIAL -- Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study.

by The FINANCIAL

July 12, 2017

3 mins read